Merck’s COVID antiviral slashes hospitalizations To view this email as a web page,
click here | | Webinar: Finding the right patients for clinical trials Tuesday, October 5 | 11am ET / 8am PT CROs that embrace these technologies could greatly improve the speed and efficiency of their trials. This webinar will explore the landscape of technologies and services that match patients to clinical trials, providing feedback from CRO executives who have experience with them. Register Now. |
Judge denies Pfizer's request to run 2 programs to subsidize patients for expensive heart drug Biden admin releases surprise billing rule detailing arbitration process UPDATED: Merck's oral COVID-19 antiviral slashes hospitalizations, prevents deaths in phase 3, sparking race to file with FDA Eli Lilly's Olympics campaign rewind: Leverage pandemic's focus on health to assert its brand and assert its point of view Siemens nets groundbreaking FDA clearance for photon-counting CT scanner Here's what major national payers are offering in Medicare Advantage for 2022 Sophia Genetics teams up with OncoDNA to automate tumor profiling Moderna report says 'human error' to blame for contamination found in 3 vaccine lots from Rovi plant HRSA opens applications for $22.5B of new provider pandemic relief funds Featured Story | By Kevin Dunleavy In ruling in favor of the Department of Health and Human Services, Southern District of New York judge Mary Kay Vyskocil denied Pfizer clearance to run two programs that would reimburse patients for their pricey heart medications Vyndaqel and Vyndamax, which cost $225,000 annually. The ruling blunts Pfizer's effort to roll back the anti-kickback policies of the U.S. read more |
| |
|---|
|
Top Stories By Robert King The Biden administration released an interim final rule that outlines the independent resolution process that will handle disputes over out-of-network charges. read more By Nick Paul Taylor The wait for an oral antiviral against COVID-19 may almost be over. Friday, Merck reported its prospect halved the risk of hospitalization and death in phase 3, spurring it to stop the study and race to get emergency use authorization. read more By Beth Snyder Bulik Eli Lilly signed on to be an Olympic sponsor for the Tokyo Games in 2019. When the pandemic postponed the Games, the pharma industry dove into researching vaccines and therapies and attention dropped for the Games and planning. But as successful vaccines and monoclonal antibody treatments came to market, Lina Polimeni, Lilly’s chief media officer, noticed consumers were suddenly picking and choosing pharma brands. read more By Conor Hale The Naeotom Alpha’s detectors are sensitive enough to measure X-rays individually, compared to current systems, which gauge the total sum of energy passing through a patient’s body. read more By Paige Minemyer Medicare Advantage open enrollment begins Oct. 15, and major national payers are outlining their plans for the coming year. read more By Andrea Park By combining their respective software tools, Sophia and OncoDNA will create a platform that automates the entire tumor profiling process, from identifying genetic variants in sequencing data all the way through suggesting the most effective treatments for those variants. read more By Kevin Dunleavy COVID-19 vaccine producer Moderna and Japanese partner Takeda have concluded that “human error” caused the presence of metallic particles in vials discovered five weeks ago in Japan. The errors occurred at a Rovi manufacturing plant in Spain, which released three vaccine lots after a fourth lot from the same production series failed an inspection. The particles were stainless steel and resulted from mistakes made during a production-line changeover, the 16-page report said. read more By Dave Muoio The distribution will recoup providers whose revenues and expenses were impacted by COVID-19, with a particular focus on smaller, rural facilities. The online application portal will be open through Oct. 26. read more |
|
